About

Molecular diagnostics are the key drivers in a more individualized pharmacotherapy such as personalized and precision medicine. The Dx-Rx Institute is committed to working with drug-diagnostic co-development and has been involved in a number of collaborations with both academia and commercial partners, which includes several PMA submissions on companion diagnostics. In addition to these activities the Dx-Rx Institute has taken part in educational activities at several European Universities and has published a number of articles on companion diagnostics and individualized pharmacotherapy, especially within oncology. The Dx-Rx Institute was established in 2009 by Dr. Jan Trøst Jørgensen as an independent institution where advice/consultancy goes hand in hand with research and development.

Please visit the company profile at Linked
Frontiers Journal Dx-Rx Institute acted as topic editor in Frontiers Research Topics issue on drug-diagnostics co-development in oncology. The journal can be downloaded free of charge from the publishers webpage .

News

Annals of Translational Medicine
Dr. Jan Trøst Jørgensen, Dx-Rx Institute has been appointed member of the Editorial Board of Annals of Translational Medicine.
Workshop on Companion Diagnostics
On January 31, 2017, Dr. Jan Trøst Jørgensen will give a lecture entitled; 'Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives'. Please visit webpage of BIO PEOPLE for further details
4th Joint EFLM-UEMS Congress - 'Laboratory medicine at the clinical interface'
At the 4th Joint EFLM-UEMS Congress, Warsaw, September 21-24th 2016, Dr. Jan Trøst Jørgensen will give a plenary lecture on the clinical application of companion diagnostics.
Most read article in Expert Review of Molecular Diagnostics
The article 'Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC' is currently the most read article in Expert Review of Molecular Diagnostics. The article can be downloaded for free from the journals website.
Editorial Board Member
The Director of the Dx-Rx Institute, Dr. Jan Trøst Jørgensen, has been appointed member of the Editorial Board for Expert Review of Molecular Diagnostics.
Most read article in Expert Review of Molecular Diagnostics.
The article 'Companion diagnostics: the key to personalized medicine' is currently the most read article in 'Expert Review of Molecular Diagnostics'. The article can be downloaded for free from the journals website.
Companion Diagnostics for Cancer - Will NGS Play a Role?
The rapid accumulation of new knowledge on tumor biology resulting from next-gen sequencing is forcing stakeholders to continually rethink companion diagnostics. Read the article by Patricia Fitzpatrick Dimond published GEN with contributions from Elizabeth Mansfield and Patricia Keegen, US FDA; Mya Thomae, Illumina and Jan Trøst Jørgensen, Dx-Rx Institute.
Finding the Right Patient for Your Drug
Interview with Jan Trøst Jørgensen (Elsevier Life Science Solutions News)
No Drug Designed For Me
Whitepaper on precision medicines and drug development from Elsevier R&D Solutions, Pharma & Life Sciences. Interview with Interviews with Dr. Jean Cui, Dr. Herbert Köppen, Dr. Scott Lusher, and Dr. Jan Trøst Jørgensen.
A comprehensive update on companion diagnostics
A special focus issue of Expert Review of Molecular Diagnostics.

Articles

Companion diagnostics - a tool to improve pharmacotherapy
Ann Transl Med 2016; 4 (24): 482
Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives.
Trends Cancer 2016; 2: 706-712.
Companion Diagnostics: From Biomarkers to Diagnostics
Reference Module in Chemistry, Molecular Sciences and Chemical Engineering (Elsevier, 2016).
The importance of predictive biomarkers in oncology drug development
Expert Rev Mol Diagn 2016; 16: 807-809
Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
Expert Rev Mol Diagn. 2016; 16: 131-133
Clinical application of companion diagnostics.
Trends Mol Med 2015; 21: 405-407.
Companion diagnostics: the key to personalized medicine.
Expert Rev Mol Diagn 2015; 15: 153-156.
Drug-diagnostics co-development in oncology
Front Oncol 2014; 4: 208.
Companion diagnostics for targeted cancer drugs
Clinical and regulatory aspects. Front Oncol 2014; 4: 105
The Role of HER2 in Gastric Cancer
Biological and Pharmacological aspects. World J Gastroenterol 2014; 20: 4526-35
A changing landscape for companion diagnostics
Expect Rev Mol Diagn 2013; 13: 667-669.
Companion Diagnostics in Oncology - current Status and Future Aspects
Oncology 2013; 85:59-68.
HER2 as a Prognostic Marker in Gastric Cancer - a Systematic Analysis of Data from the Literature
J Cancer 2012; 3: 137-144
A challenging drug development process in the era of personalized medicine
Drug Discov Today 2011; 16: 891-897.
Targeted HER2 Treatment in Advanced Gastric Cancer.
Oncology 2010; 78: 26-33.